AI-generated summary
This review examines research on photobiomodulation for retinal diseases, covering mechanisms and clinical outcomes, based on literature searched in PubMed through April 2015. The authors report that PBM is low-cost and non-invasive, with promising early clinical reports and numerous preclinical animal studies. They state that large-scale clinical trials will be needed to establish therapeutic ranges and clarify how it works.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract notes that large-scale clinical trials are still needed, and the evidence base relies on early clinical reports and animal studies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on ijo.cn.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Retina, Laser, Age-related macular degeneration, Near-infrared, Neuropathy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.